Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.58 |
| ▸ | CNR1 | P21554 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5445907 | 0.93 | MAPT (0.75) | MAPTKDM4ENOX1ALDH1A1NPC1 | |
| SCHEMBL8956455 | 0.93 | MAPT (0.75) | MAPTKDM4ENOX1ALDH1A1NPC1 | |
| SCHEMBL6811504 | 0.87 | RAB9A (0.68) | MAPTKDM4ENOX1ALDH1A1NPC1 | |
| SCHEMBL6811493 | 0.85 | ALDH1A1 (0.67) | MAPTKDM4ENOX1ALDH1A1NPC1 | |
| SCHEMBL5081276 | 0.84 | NOX1 (0.85) | MAPTKDM4ENOX1ALDH1A1NPC1 | |
| SCHEMBL8956349 | 0.84 | NOX1 (0.85) | MAPTKDM4ENOX1ALDH1A1NPC1 | |
| SCHEMBL3860141 | 0.84 | KDM4E (1.00) | MAPTKDM4ENOX1ALDH1A1NPC1 | |
| SCHEMBL526059 | 0.84 | MAPT (0.63) | MAPTKDM4ENOX1ALDH1A1NPC1 | |
| SCHEMBL11060530 | 0.83 | CNR1 (0.70) | MAPTKDM4ENOX1ALDH1A1GAA | |
| SCHEMBL11074089 | 0.83 | HTT (0.66) | MAPTKDM4ENOX1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152242-A1 | 2,3-Substituted Fused Pyrimidin -4 (3H)-Ones as VR1 Antagonists | MERCK SHARP & DOHME LTD. (GB) | 2011-06-23 | — | — | US | disclosed |
| US-20090298856-A1 | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) | BROWN REBECCA ELIZABETH | 2009-12-03 | — | — | US | disclosed |
| US-20090233947-A1 | 2,3-Substituted fused bicyclic pyrimidin-4(3H)-ones which modulating the function of the vanilloid -1 receptor (VR1) | MERCK SHARP & DOHME LTD. (GB) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298856-A1 | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) | TRPV1, TRPV2, TRPV4 | MAPT 3420/4885KDM4E 4094/4885NOX1 1923/4885 |
| US-20090233947-A1 | 2,3-Substituted fused bicyclic pyrimidin-4(3H)-ones which modulating the function of the vanilloid -1 receptor (VR1) | TRPV1, TRPV2, TRPV3 | MAPT 4073/4885KDM4E 4297/4885NOX1 2427/4885 |
| US-20110152242-A1 | 2,3-Substituted Fused Pyrimidin -4 (3H)-Ones as VR1 Antagonists | NR2C2, NR3C2, NR2E3 | MAPT 4878/4885KDM4E 4398/4885NOX1 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.